Based in New York City, Lexeo is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. I have the privilege of leading the Technical Operations and CMC teams.

I have had the privilege of being a team member of some exceptional bioprocess development and manufacturing teams for complex biopharmaceutical products (Merck & Co.; Seres Therapeutics; and currently, Turnstone Biologics). I have devoted some of my personal time to consulting and advising for research groups/teams that believe excellence in CMC development is critical to accomplishing their mission, including Dr. Eric Pamer at the Duchossois Family Institute DFI at the University of Chicago Medicine. The DFI promotes wellness through groundbreaking science on the immune system, genetics, the microbiome, and their shared environments. The vision is to bring translational capabilities to a state of the art academic center, to go from the research bench to first-in-human clinical investigations, all within the same team and organization, with a sense of urgency and velocity that is unparalleled. We are in the process of designing, building, and enabling a cGMP microbiome manufacturing center -- a best-in-class and in many instances first-in-class capability -- under this unique intersection of academic and clinical research.

Proud member of the #AUREGENATORS.... leading manufacturing, supply chain, quality, process development, CMC development and analytical development.

Incredible privilege and responsibility to continue building a high-performing team responsible for all aspects of Turnstone's bioprocess development, manufacturing, QC, supply chain, and CMC strategy and operations, across a differentiated viral immunotherapy and TIL cell therapy technology pipeline. Further, I am partnering with exceptional colleagues on the Executive Team and Board of Directors to realize the full potential of the broader Turnstone team to ultimately bring products to the treatment landscape that will make the difference for people -- our families, our friends, our neighbors, our colleagues, and the strangers we share this life with -- that are suffering with cancer every single day. Zero time to waste.

Responsible for leading all activities related to bioprocess, analytical, and formulation development, as well as CMC enabling activities related to manufacturing, supply chain, quality control, and long-term strategy. As a member of the Executive Leadership Team, I have the privilege of working with a world-class group of colleagues and scientifically driven leaders that are re-engineering and re-imagining viral immunotherapies. The best part of my role and responsibility is serving as lead 'team-builder', being the very best coach, mentor, and biggest fan I can be of a highly capable group of scientists and engineers in the Technical Operations team. Every day our quest towards becoming a better high-performing team is realized, one accomplishment at a time.Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone’s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing time to treatment for patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.

Turnstone Biologics, Inc., is leading a first-in-class oncolytic viral immunotherapy that combines a bioselectd and engineered oncolytic virus to directly lyse tumors with a potent vaccine technology to drive tumor-antigen specific T-cell responses of unprecedented magnitude. I am responsible for leading the BioProcess development and Manufacturing team at Turnstone, composed of an exceptional group of scientists, engineers, and biotechnology professionals.

Seres Therapeutics (NASDAQ: MCRB) is the leading microbiome company, developing new therapies for patients that restore and maintain healthy microbiomes. Bioprocess Development plays a unique role in discovery, development, and commercialization activities at Seres, responsible for enabling pre-clinical and clinical hypotheses to be realized.

Over the past century, antibiotics, changes in nutrition, and other environmental factors have dramatically altered the shape of the human microbiome. These microbial ecologies residing in and on the human body are now understood to be vital to our health. Seres Therapeutics (originally Seres Health) is pioneering a new approach to fundamentally restore and maintain healthy microbiomes. The Company was conceived of and launched by VentureLabs, Flagship Ventures' Innovation Foundry, and has recruited the world’s leaders in the scientific and clinical aspects of the human microbiome.

Functional and project leadership for upstream process development activities related to life-cycle management and commercialization of mammalian cell culture based processes, as well as continued Integrated Development and Supply Team Leadership (see previous role).

Integrated Development and Supply Leader responsible for building strategy around and leading CMC activities related to life-cycle management of existing vaccine portfolio, as well pipeline vaccine activities. Specific focus in live virus vaccines, with integration of process development, analytical, formulation, quality, regulatory, clinical, and manufacturing strategy and execution.

As Fermentation Development Lead within the Vaccines Research & Development organization I am responsible for guiding strategy and technology development of fermentation. Specifically, I manage a team of scientists and engineers focused on developing cost-effective, sustainable, cutting edge, and robust bio-processes focused on enabling a diverse portfolio of vaccines.

Supervisors: Dr. Hugh George, Dr. Wayne HerberFermentation & Cell Culture, BioProcess Research & DevelopmentMerck Research Labs

Supervisors: Professor Jens Nielsen, Professor Lisbeth OlssonThe Systems Biology Group of Professor Jens Nielsen has transferred to the Chalmers University of Technology (CTU). Consequently, my research activities have transferred and I will officially be awarded a Chemical and Biological Engineering PhD from CTU.

Supervisors: Lisbeth Olsson and Jens NielsenSaccharomyces cerevisiae is a robust expression platform technology for numerous therapeutic agents, value-added and high value-added chemical intermediates. In 2004, based upon a critical analysis to identify the top building blocks that may be produced from biomass and subsequently converted to high-value bio-based chemicals, the US Department of Energy identified succinic acid (C4H2O2(OH)2) as a top ten building block. The objective of this Ph.D. project is to use metabolic engineering to over-produce succinic acid. S.cerevisiae tolerates relatively low pH (4.0-5.50) with minimal impact on biomass growth, permitting direct expression of the associated succinic acid. Furthermore, an integrated metabolic engineering and systems biology approach for directing carbon flux towards C4 organic acids in S.cerevisiae will further elucidate mechanistic understanding of how fluxes in the central carbon metabolism are controlled.

Biotechnology startup evolving from undergraduate research completed at Beth Israel Deaconess Medical Center of Harvard Medical School. Mouse Specifics, Inc., is a group of engineers focussed on developing non-invasive technology for measurement of physiological parameters in rodent animal models. This work resulted in numerous publications and two issued US patents. President & Founder: Dr. Thomas G. Hampton, Assistant Professor at Harvard Medical School.